Challenges remain in fight against TB, U.N. Secretary-General says

On World Tuberculosis Day, recognized on March 24, U.N. Secretary-General Ban Ki-moon "said that while there has been much progress since the World Health Organization (WHO) declared TB a global health emergency two decades ago, there are still challenges to be met, mainly stopping the spread of multidrug-resistant TB, also known as MDR-TB, which threatens to reverse the gains achieved in past years," the U.N. News Centre reports. "New diagnostics, new drugs and the promise of new vaccines have the potential to further accelerate progress against TB, which still kills 1.4 million people a year -- more than any infectious disease other than AIDS. But two obstacles stand in the way," he said, noting drug-resistant TB and a need for additional funding. "WHO Director-General Margaret Chan stressed that while curing MDR-TB is feasible, it takes 20 to 24 months of treatment with expensive and toxic drugs, some of which need to be administered by injection and some of which are in short supply," the news service adds, noting she "warned that nearly four percent of people newly ill with TB are resistant to multiple drugs right from the start" (3/24).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First-generation antihistamine drugs could increase seizure risk among young children